# Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

> **NCT02979613** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 490 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** TAF
- **DRUG:** TDF
- **DRUG:** TAF Placebo
- **DRUG:** TDF Placebo

## Key facts

- **NCT ID:** NCT02979613
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-29
- **Primary completion:** 2018-09-10
- **Final completion:** 2020-01-30
- **Target enrollment:** 490 (ACTUAL)
- **Last updated:** 2020-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02979613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02979613, "Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02979613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*